Short Interest in Helius Medical Technologies, Inc. (NASDAQ:HSDT) Expands By 247.1%

Helius Medical Technologies, Inc. (NASDAQ:HSDT) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 66,300 shares, a growth of 247.1% from the February 28th total of 19,100 shares. Currently, 1.9% of the company’s shares are short sold. Based on an average daily volume of 4,400,000 shares, the short-interest ratio is presently 0.0 days.

Institutional Trading of Helius Medical Technologies

An institutional investor recently bought a new position in Helius Medical Technologies stock. Virtu Financial LLC purchased a new stake in shares of Helius Medical Technologies, Inc. (NASDAQ:HSDT) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 46,510 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 1.25% of Helius Medical Technologies at the end of the most recent quarter. Institutional investors own 18.63% of the company’s stock.

Helius Medical Technologies Stock Up 4.5 %

NASDAQ:HSDT opened at $0.42 on Friday. The stock has a fifty day simple moving average of $0.54 and a 200 day simple moving average of $0.59. The firm has a market capitalization of $1.57 million, a price-to-earnings ratio of -0.07 and a beta of 1.62. Helius Medical Technologies has a 1-year low of $0.37 and a 1-year high of $7.19.

Helius Medical Technologies (NASDAQ:HSDT) last announced its earnings results on Tuesday, March 25th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.09). Helius Medical Technologies had a negative return on equity of 244.82% and a negative net margin of 1,764.74%. The firm had revenue of $0.15 million during the quarter, compared to analyst estimates of $0.10 million.

About Helius Medical Technologies

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.